Jazz and Zymeworks spell out HER2 bispecific win news2026-01-06T20:46:28+00:00January 6th, 2026|Endpoints News|
J&J plans late-stage trial for lupus candidate after Phase 2 successnews2026-01-06T19:11:01+00:00January 6th, 2026|Endpoints News|
Lilly goes back to Nimbus for an oral obesity drug in $55M dealnews2026-01-06T13:00:47+00:00January 6th, 2026|Endpoints News|
Appeals court rules against NIH’s indirect cost cut plan news2026-01-05T23:54:56+00:00January 5th, 2026|Endpoints News|
HHS urges Supreme Court to decline AstraZeneca’s petition over Medicare price negotiationsnews2026-01-05T19:42:19+00:00January 5th, 2026|Endpoints News|
US to stop recommending six vaccines for all kids, prioritizing individual choice and higher-risk groupsnews2026-01-05T19:02:32+00:00January 5th, 2026|Endpoints News|
Crinetics reports robust full-quarter sales for rare disease drug Palsonifynews2026-01-05T18:14:15+00:00January 5th, 2026|Endpoints News|
Sanofi doubles down on Earendil in $160M near-term dealnews2026-01-05T15:03:58+00:00January 5th, 2026|Endpoints News|
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cashnews2026-01-05T10:09:50+00:00January 5th, 2026|Endpoints News|
AbbVie does T cell engager deal in China for Zelgen’s DLL3-targeted drugnews2025-12-31T16:18:48+00:00December 31st, 2025|Endpoints News|
